Voyager Therapeutics (VYGR) Expected to Post Earnings on Wednesday

Voyager Therapeutics (NASDAQ:VYGR) is anticipated to post its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Voyager Therapeutics to post earnings of ($0.55) per share and revenue of $4.5190 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. The company had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $8.79 million. On average, analysts expect Voyager Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Voyager Therapeutics Stock Down 1.6%

Voyager Therapeutics stock opened at $3.04 on Wednesday. The company has a fifty day simple moving average of $3.51 and a 200-day simple moving average of $3.78. The firm has a market capitalization of $183.68 million, a price-to-earnings ratio of -1.54 and a beta of 1.27. Voyager Therapeutics has a 52-week low of $2.88 and a 52-week high of $5.55.

Wall Street Analysts Forecast Growth

VYGR has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Monday, July 13th. Finally, HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.50.

Institutional Trading of Voyager Therapeutics

Several institutional investors have recently made changes to their positions in the company. American Century Companies Inc. increased its stake in Voyager Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after acquiring an additional 6,748 shares during the last quarter. OMERS ADMINISTRATION Corp grew its holdings in shares of Voyager Therapeutics by 15.4% during the 4th quarter. OMERS ADMINISTRATION Corp now owns 83,012 shares of the company’s stock worth $326,000 after purchasing an additional 11,062 shares during the period. Walleye Capital LLC acquired a new stake in shares of Voyager Therapeutics during the 4th quarter worth about $219,000. Jacobs Levy Equity Management Inc. purchased a new stake in Voyager Therapeutics in the 1st quarter valued at about $218,000. Finally, BNP Paribas Financial Markets lifted its position in Voyager Therapeutics by 682.5% in the third quarter. BNP Paribas Financial Markets now owns 42,339 shares of the company’s stock valued at $198,000 after buying an additional 36,928 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.